SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
Cette joint-venture permettra de créer près de 150 emplois sur un nouveau site
Discover our Type I Excellence Center of Saint-Quentin-Lamotte
Saint-Quentin-Lamotte (France) is our flagship facility:
• 270 skilled and dedicated employees,
• 11,000 m² of state-of-the-art manufacturing,
• ISO 8 clean room
💡 SQLM produces 1 million Type I molded glass vials every single day and has invested in SEALIAN. This internal treatment protects sensitive drug through its barrier effect and enables optimal release due to its hydrophobic properties, making it suitable for viscous solutions.
She makes sure everything runs smoothly – from demand planning to customer delivery 🤝
Today, let's meet Maud Rolinat, Supply Chain manager at Saint Quentin La Motte (SQLM), SGD Pharma’s flagship facility in northern France for Type I molded glass vials.
Her role involves working closely with production teams, customer service, procurement and logistics partners to ensure an efficient and reliable supply chain. The result – impeccable customer satisfaction.
🌸 International Women’s Day - March 8, 2026 🌸
At SGD Pharma, gender equality is not a one-off goal, it’s a core business strategy, a driver for innovation, performance, and sustainability.
Our latest 2025 Gender Equality Index result speaks for itself: SGD SA: 94/100
Behind this score are concrete actions:
Promoting gender balance in recruitment and career development processes
Monitoring diversity and inclusion indicators to track progress and refine initiatives
🎓 What if your 2026 apprenticeship started at SGD Pharma?
We are proud to launch our Campus Campaign 2026 in France, opening new opportunities for students to join our teams and develop their skills through apprenticeships in technical, engineering and support functions (such as Procurement, Finance, IT, Human Resources, etc.).
At SGD Pharma, apprenticeships are about more than gaining experience, they are about learning, sharing knowledge and building the next generation of talent.
SGD Pharma will launch My Sterinity Nasal at The DCAT (Drug, Chemical & Associated Technologies Association) Week 2026
We’re thrilled to showcase My Sterinity Nasal, which will be developed with Prince Sterilization Services.
This platform combines SGD Pharma’s Type I U-save vials with Prince’s RTU sterilization expertise, offering validated, ready-to-use packaging for high-value nasal therapies.
📍We’re really excited to be here at DCAT (Drug, Chemical & Associated Technologies Association) New York 2026!
🎯Type I glass is becoming the material of choice for the global nasal market ($10.3bn) as more advanced and long-term treatments for Alzheimer’s, Parkinsons, multiple sclerosis and depression, require primary packaging combining sterility, consistency and precision dosing.
🏆 CDP Awards Europe: SGD Pharma, now part of the CDP A List, has been recognized for demonstrating true climate leadership, not only through ambition, but through measurable performance and robust governance.
The award was received by Olivier Rousseau, CEO of SGD Pharma, and ESG team members.
Paris La Défense, FRANCE – 17 mars 2026 : SGD Pharma, leader mondial sur le marché des solutions d'emballage primaire en verre pharmaceutique, annonce une collaboration stratégique franco-américaine en OEM avec Prince Sterilization Services, LLC afin de valider des solutions de conditionnement primaire en verre de type I prêtes à l’emploi (RTU) destinées au marché nord‑américain.
